Medscape

Novel Antisense Inhibitors Cut Lp(a) Levels in Small Phase 2 Studies

SAN DIEGO, CA — Two novel antisense oligonucleotide therapies in development significantly reduced levels of lipoprotein(a) in individuals with elevated Lp(a) in two clinical trials, according to a ...
Healio

First investigational oral therapy lowers Lp(a) in phase 2 study

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. An investigational oral drug lowered lipoprotein(a) ...
Morning Overview on MSN

Novartis, Amgen, Lilly target Lp(a) in bid for next heart drugs

Statins cannot touch it. Neither can diet or exercise. Lipoprotein(a), a cholesterol-like particle hardwired into a person’s ...
Medscape

Zerlasiran siRNA Drug Lowers Lp(a) by 90% in Phase 2 Results

Silence Therapeutics announced positive topline 36-week data from its ongoing phase 2 study of zerlasiran, a long-acting agent directed at lowering Lp(a) levels. In a statement, the company said the ...